CompletedPHASE1, PHASE2NCT02550678

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

Studying Gorlin syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Ascend Biopharmaceuticals Ltd
Principal Investigator: Lynda Spelman
Veracity Clinical Research Pty Ltd.
Intervention: ASN-002(biological)
Enrollment: 16 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2017

Study locations (4)

St George Dermatology and Skin Cancer Centre, Kogarah, New South Wales, Australia
Siller Medical T/A Central Brisbane Dermatology, Brisbane, Queensland, Australia
Veracity Clinical Research, Brisbane, Queensland, Australia
Sinclair Dermatology, Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02550678 on ClinicalTrials.gov

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06050122
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →

← Back to all trials